ArticleCardiology journal2022
First clinical experience of high-power ablation of atrial fibrillation with a novel contact force-sensing gold-tip catheter.
Article in Cardiology journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundContact force (CF)-sensing catheters are commonly used in the field of radiofrequency (RF) ablation to treat atrial fibrillation (AF). Increasing ablation power (e.g., 50 W) has been suggested as a method to reduce procedure times whilst creating safe and lasting lesions.
methodsWe report the first clinical evidence of a 50 W point-by-point RF ablation in 25 consecutive patients with symptomatic AF using a novel CF-sensing catheter with a gold tip (AlCath Force, Biotronik). We collected and analyzed procedural and ablation parameters. The safety and efficacy of the catheter were evaluated.
resultsAltogether, 985 RF lesions in 25 patients were created with a mean number of 39.4 ± 16.3 lesions per patient. The total skin-to-skin procedure time was 116.1 ± 35.1 min, and the mean total area dose product was 10.9 ± 5.1 Gy*cm2. The mean RF time per procedure was 13.2 ± 6.6 min. The mean RF time per lesion was 20.2 ± 8.4 s. The mean CF was 15.7 ± 7.6 g. We observed a mean force time integral of 274.7 ± 11.1 gs (range: 53 to 496 gs). Acute procedural success, defined as entrance and exit block in all pulmonary veins, could be obtained in all cases. No procedure- or device-related serious adverse events were observed. No audible steam pops occurred. Optical inspection of the catheter after the procedure showed neither charring nor clotting.
conclusionsWe provide the first evidence for the safety and efficacy of 50 W ablation using the AlCath Force gold-tip catheter. These data must be supported by a larger multi-center study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.